Want to join the conversation?
$VRTX said that it expects the vast majority of the eligible patients ages 12 and older in the U.S. will initiate treatment with Orkambi by the end of this year. The company expects to deliver quarter to quarter revenue growth for Orkambi beginning in 2Q16 and continuing through the end of 2016 and into 2017.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)